Novo Nordisk submits proposal to acquire Metsera, Inc.

Summary by AI BETAClose X

Novo Nordisk has submitted a proposal to acquire Metsera, Inc. for 56.50 USD per share in cash, representing an approximate aggregated equity value of 6.5 billion USD and an enterprise value of approximately 6.0 billion USD. The proposal also includes contingent value rights (CVRs) of up to 21.25 USD per share in cash, potentially adding up to 2.5 billion USD, based on achieving specific clinical and regulatory milestones. The cash consideration will be paid at signing for non-voting preferred stock representing 50% of Metsera’s share capital, with the CVRs issued upon closing for the remaining shares. The Metsera board of directors is currently reviewing the proposal.

Disclaimer*

UK 100

Latest directors dealings